托法替布与巴瑞替尼的血栓栓塞安全性报告:WHO VigiBase分析
基于WHO VigiBase数据库2019年4月数据,对托法替布(n=40017)和巴瑞替尼(n=2138)的个体病例安全性报告进行不成比例分析。欧洲地区托法替布与深静脉血栓(ROR 2.37)和肺血栓/肺栓塞(ROR 2.38)报告增加相关,巴瑞替尼亦显示约三倍报告 odds 增加;美国仅托法替布与肺血栓报告升高相关。研究支持高血栓风险患者慎用托法替布,且不能排除JAK抑制剂的类效应。
要点
- 欧洲托法替布DVT报告ROR 2.37,PT/PE报告ROR 2.38。
- 欧洲巴瑞替尼DVT报告ROR 3.47,PT/PE报告ROR 3.44。
- 美国托法替布仅PT报告ROR 2.05升高,无巴瑞替尼报告。
核心结论
- 研究支持当前对高血栓栓塞风险患者慎用托法替布的建议。
- 巴瑞替尼患者特征相似且报告升高,不能排除JAK抑制剂的类效应。
研究设计与样本
- 基于WHO全球数据库VigiBase于2019年4月检索的托法替布和巴瑞替尼个体病例安全性报告。
- 托法替布ICS Rs n=40017,巴瑞替尼ICS Rs n=2138。
- 主要结局为深静脉血栓(DVT)和肺血栓(PT)或肺栓塞(PE)。
- 采用报告比值比(ROR)及95%置信区间进行不成比例分析,并按全球、欧洲和美国分层。
主要发现
- 在托法替布和巴瑞替尼ICS Rs中,报告DVT或PT/PE的患者年龄更大,且促血栓药物或抗血栓治疗报告更多。
- 欧洲托法替布与DVT报告增加相关(ROR 2.37,95% CI 1.23-4.56),与PT/PE报告增加相关(ROR 2.38,95% CI 1.45-3.89)。
- 欧洲巴瑞替尼与DVT报告增加相关(ROR 3.47,95% CI 2.18-5.52),与PT/PE报告增加相关(ROR 3.44,95% CI 2.43-4.88)。
- 美国托法替布仅与PT报告升高相关(ROR 2.05,95% CI 1.45-2.90),美国无巴瑞替尼ICS Rs报告。
临床怎么用
- 对高血栓栓塞风险患者使用托法替布时应谨慎,并评估已有血栓风险因素。
- 使用巴瑞替尼时也应关注血栓栓塞事件报告信号,尤其在欧洲数据背景下。
局限性
- 研究为基于自发报告数据库的不成比例分析,不能确立因果关系。
- 美国无巴瑞替尼ICS Rs报告,限制该地区巴瑞替尼比较。
- 报告DVT或PT/PE患者年龄更大且更多使用促血栓或抗血栓药物,提示可能存在既存血栓风险或事件。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The Janus kinase (JAK) inhibitors tofacitinib and baricitinib are new treatments for rheumatic diseases. Recent concerns regarding the risk of thrombosis have led to warnings by competent authorities. We therefore aimed to examine the thromboembolic safety signal for tofacitinib and baricitinib. METHODS: Individual case safety reports (ICSRs) for tofacitinib and baricitinib were retrieved from the World Health Organization global database VigiBase in April 2019. Primary outcomes were deep vein thrombosis (DVT) and pulmonary thrombosis (PT) or pulmonary embolism (PE). Patient demographics were summarized and then stratified by outcome. Disproportionality analyses were conducted by estimating the reporting odds ratios (RORs) and 95% confidence intervals (CIs) worldwide, and stratified by either Europe or the US. RESULTS: In both the tofacitinib (n = 40,017) and baricitinib (n = 2138) ICSRs, patients with reported DVT or PT/PE were older and had higher reporting of prothrombotic medications or antithrombotic treatments, suggesting a pre-existing thromboembolic risk/event. In Europe, tofacitinib was associated with increased reporting for DVT (ROR 2.37, 95% CI 1.23-4.56) and PT/PE (ROR 2.38. 95% CI 1.45-3.89). For baricitinib, a threefold increased reporting odds was observed for DVT (ROR 3.47, 95% CI 2.18-5.52) and PT/PE (ROR 3.44, 95% CI 2.43-4.88) in Europe. In the US, tofacitinib was only associated with an elevated ROR of PT (ROR 2.05, 95% CI 1.45-2.90) and no baricitinib ICSRs were reported. CONCLUSION: This study supports the current recommendation for cautious use of tofacitinib in patients with high thromboembolic risk. Moreover, with a similar patient profile and elevated reporting for baricitinib, a potential class effect of JAK inhibitors cannot be ruled out.
引用
- Vallejo-Yagüe E, Weiler S, Micheroli R, et al. Thromboembolic Safety Reporting of Tofacitinib and Baricitinib: An Analysis of the WHO VigiBase. Drug Saf. 2020. PMID: 32533433. doi:10.1007/s40264-020-00958-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。